Sandoz has recently announced the approval of the AirFluSal Forspiro salmeterol/fluticasone DPI by Norway and Bulgaria, bringing the total number of European approvals to 7. The inhaler has also been approved in Denmark, Germany, Sweden, Hungary, and Romania.
The Norwegian approval is for the 50/250 µg and 50/500 µg dosages for the treatment of asthma and for symptomatic treatment of COPD. Bulgaria approved only the 50/500 µg dosage for both indications.
Read the Sandoz press release on the Norwegian approval.
